acute heart failure
Conditions
Interventions
Experimental group:On the basis of the control group, sacubitril valsartan tablets 100mg twice a day (50mg twice a day for patients not taking ARB drugs or taking low-dose ARB drugs and for patients w
Control group:Heart failure comprehensive pharmacotherapy was administered alone, including loop diuretics, ß blockers, mineralocorticoid receptor antagonists (all at identical doses), inotropic agent
Sponsors
Quzhou Kecheng District People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.All patients meet the diagnostic criteria outlined in the "Guidelines for Primary Care Diagnosis and Treatment of Acute Heart Failure (2019 Edition)"; 2.Meet the diagnostic criteria for diuretic resistance: daily intravenous furosemide >= 80 mg, or equivalent daily dose of other diuretics, yet unable to achieve adequate urine output (0.5–1.0 mL/kg/h); 3. Complete baseline information available and participation in all trial procedures; 4. Informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. Patients with cardiogenic shock, severe respiratory diseases with marked hypoxemia and hemodynamic instability, hematologic disorders, autoimmune diseases, severe hepatic or renal disease (eGFR <= 30 mL/min/1.73 m^2), severe arrhythmias, myocarditis, acute myocardial infarction, severe electrolyte disturbances, acid-base imbalance, severe infections, or malignancies; 2. Patients with contraindications to sacubitril/valsartan or SGLT-2 inhibitors; 3.Patients currently taking ACE inhibitors; 4.Patients with psychiatric disorders or communication barriers; 5. Patients with a history of drug allergies; 6.Patients who have participated in other clinical trials within the past two months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24h urine output;Weight;6-minute walk test results; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum creatinine level;N-terminal pro-B-type Natriuretic Peptide;Diuretic efficiency;Dyspnea score;Changes in the patient's heart function; | — |
Countries
China
Contacts
Public ContactMinglei Zhang
Quzhou Kecheng District People's Hospital
Outcome results
None listed